Polio vaccine history: what really happened — examining the timeline, diagnostic reclassification, DDT correlation, and the Salk/Sabin vaccine record using primary source documents.
According to Siri, the narrative that the Salk polio vaccine eradicated paralytic polio is one of the most entrenched myths in vaccinology — contradicted by contemporaneous scientific consensus from the 1940s–1960s, diagnostic criteria changes that created a statistical artifact, and evidence that the Salk vaccine may not have been the primary driver of the post-1955 decline in reported polio cases.
According to Siri, the polio virus was endemic and largely benign for millennia — infecting generations of humans with few documented harms. Albert Sabin, inventor of the oral polio vaccine, wrote in 1947: "paralytic poliomyelitis became an epidemic disease only a little more than fifty years ago" and that "the epidemic outbursts … in the past thirty to forty years, are events that could not readily have been missed in the past."
Key anomalies of the polio epidemic (as documented by 1940s–1960s scientists):
1. Only in developed countries: Polio epidemics with paralysis occurred exclusively in North America, Europe, and Oceania. US, British, and Australian military members stationed in developing countries contracted paralytic polio, while the surrounding local populations — who were highly infected with the polio virus — showed no paralysis. The Philippines: 16 of 17 cases at a Manila hospital were Americans; meanwhile, 90% of Filipino civilians had polio antibodies (meaning widespread exposure) but no epidemic.
2. Seasonal pattern: Cases clustered in summer and early autumn — Sabin called this a puzzle he could not explain.
3. Domestic animals: Paralysis in domestic animals was repeatedly documented alongside human polio epidemics, even though the polio virus cannot infect animals.
4. Natural decline before the vaccine: Polio peaked in 1952 in the US (~3,000 deaths) then began declining before the first Salk vaccine was introduced in 1955. The 1960 expert meeting report noted: "Both [polio and infectious hepatitis] diseases were in a natural decline when the Salk vaccine was introduced in 1955."
5. Developing countries: When polio appeared in developing countries starting in the 1970s (India, Afghanistan, Somalia), health authorities attributed it to poor sanitation — directly contradicting the "improved hygiene" theory used to explain the earlier developed-world epidemic.
The main theory proposed to explain polio's emergence was that improved hygiene delayed infant exposure until maternal antibodies had waned, leaving children vulnerable. Sabin explicitly rejected this: serological surveys showed that 80–90% of children in developing countries (where there was no polio epidemic) still lacked antibodies at the end of their first or second year of life — meaning they were encountering the virus late, just as the hygiene theory predicted — yet they did not develop paralytic polio. Sabin called the improved hygiene theory "untenable."
A 1960 meeting of leading national polio experts (including directors from major vaccine manufacturers, biostatisticians, and government delegates) documented what contemporaneous scientists considered basic uncontested facts about the Salk vaccine:
Before 1955 (pre-vaccine): Paralytic polio was diagnosed with symptoms at least 24 hours apart — no laboratory confirmation required.
After 1955 (post-Salk vaccine): Paralytic polio required paralysis present at least 60 days apart AND laboratory confirmation of the polio virus.
Professor Greenberg (head of biostatistics, University of North Carolina; former chair of the Committee on Evaluation and Standards, American Public Health Association) stated:
> "Thus, simply by changes in diagnostic criteria, the number of paralytic cases was predetermined to decrease in 1955-1957, whether or not any vaccine was used."
The 1960 expert report also noted:
Dr. Greenberg concluded: "the significant decline in paralytic polio after introduction of the Salk vaccine was … an artifact of these factors and not a result of an effective vaccine."
Dr. Kleinman (Minnesota Dept of Health): "If polio antibodies mean anything in respect to protection, then I am forced to conclude that much of the Salk vaccine we have been using is useless. Over 50% of vaccinated children do not have antibodies to Types I and III, and 20% lack antibodies to Type II."
Dr. Cox (Director of Virus Research, Lederle — a major Salk vaccine manufacturer): "The killed vaccine does a poor job against Type I, however, which causes 85% of paralytic cases, and against Type III, which causes about 12%. In other words, the killed vaccine is doing its best job against the least important type."
Dr. Ratner: "Safety testing was inadequate when Dr. Salk developed his vaccine and when the vaccine was commercially prepared for the field trials of 1954 and for licensing and use in 1955."
Professor Meier (biostatistician, University of Chicago): "How is it that today you hear from the members of this panel that the Salk vaccine situation is confused; yet what everybody knows from reading the newspapers … is that the situation … was and is marvelous? The reason for this discrepancy lies … in a new attitude of many public health and publicity men. It is hard to convince the public that something is good. Consequently, the best way to push forward a new program is to decide on what you think the best decision is and not question it thereafter, and further, not to raise questions before the public or expose the public to open discussion of the issues."
Siri notes that countries which used only the inactivated Salk vaccine (which does not prevent transmission — see Herd Immunity) nonetheless saw polio disappear, including among the unvaccinated. He argues this supports the theory that some environmental factor drove the polio epidemic and, as that factor abated, polio cases declined independently of vaccination.
Siri mentions that ICAN petitioned the FDA to revoke licensure of a specific 1990 polio vaccine (not the Salk or Sabin vaccines) — licensed through a clinical trial with a three-day safety observation window and no control group. This vaccine uses monkey kidney cells with chromosomes modified to be immortal (cancer-like) as an ingredient. The New York Times headlined this as "Kennedy's Lawyer Asked FDA to Revoke Approval of the Polio Vaccine," creating national outrage — while omitting that five other licensed polio vaccines would remain available even if the petition were granted.
Siri argues that polio represents the clearest case of how vaccine mythology is constructed:
1. A natural decline in disease (pre- and independently of the vaccine) is attributed to the vaccine
2. Diagnostic criteria are changed after vaccine introduction, artificially reducing case counts
3. Leading scientists of the era who questioned efficacy are ignored by subsequent history
4. Emotional public attachment to the narrative makes rational discussion nearly impossible
5. The pattern closely mirrors how Covid-19 vaccine effectiveness was presented
Herd Immunity, Pre-Licensure Safety Testing, FDA, CDC, ICAN
Frequently Asked Questions